



A Guide To NRG1 Gene Fusion Clinical Trials

Massive Bio, Inc.

Understanding NRG1 Gene Fusions

- Neuregulin 1 (NRG1) gene fusions in tumors are often oncogenic drivers, causing the cancer to grow and spread more quickly than cancers without a mutation.
- NRG1 is a gene of the epidermal growth factor family and is involved in the proliferation and survival of cells.
- Genomic tests are used to analyze a biopsy of the tumor for NRG1 mutations that may respond to targeted therapies.
- With the help of genomic tests, better targeted cancer treatment can be planned, including personalized treatments such as targeted therapies.




NRG1 Fusions are rare but can occur in pancreatic, lung, breast, esophageal, prostate, and several other cancer types

How Clinical Trials Can Help

There are 9 active clinical trials involving NRG1 gene alterations for many different cancer types taking place in the United States. Participating in a clinical trial not only progresses much-needed research, but also gives patients access to these new innovative therapies years before the general population.

The new treatments investigated in today's cancer clinical trials are:

- Targeted therapies for new biomarkers
- Immunotherapy using new monoclonal antibodies
- Combinations of chemotherapies with other drugs
- New methods of surgery



**FIND TRIALS YOU'RE
ELIGIBLE FOR NOW**

How We Can Help

At Massive Bio, our mission is to enable cancer patients to have equal access to cutting-edge therapies and clinical trials, regardless of their location and/or financial stability.

Our Artificial Intelligence (AI) powered Clinical Trial Matching System connects patients and their treating oncologists to clinical trials according to their unique cancer case.

We enlist dedicated staff to collect medical records and treatment history and match patients to eligible trials near their home. We provide full support throughout your enrollment process to ensure logistics are handled so you can concentrate on your health.



Massive Bio Launches Industry's First NASA-Style, Oncology Clinical Trial Command Center



The National Cancer Institute Awarded Contract to Develop an Oncology Based Artificial Intelligence-Enabled Clinical Trial Recruitment Tool

Contact Information



Fiona Evans
Lead Patient Advocate
Phone: 646.586.2753
Email: fevans@massivebio.com



Jackie Bement
Patient Advocate
Phone: 646.453.7362
Email: jbement@massivebio.com

Email: Support@massivebio.com

Website: www.massivebio.com

A patient advocate will contact you in 24 hours after downloading this guide to further discuss your eligibility for clinical trials. To begin receiving your complimentary clinical trial matching results, complete the Synergy-AI agreement below.

[**SYNERGY-AI Clinical Trial Matching**](#)



OUR MOBILE APP CAN HELP YOU FIND CLINICAL TRIALS

The SYNERGY-AI Cancer Clinical Trial Finder App is available in the IOS and Google Play Stores Now.

